SK282227B6 - Farmaceutický prostriedok na liečenie hyperglykémie - Google Patents

Farmaceutický prostriedok na liečenie hyperglykémie Download PDF

Info

Publication number
SK282227B6
SK282227B6 SK749-95A SK74995A SK282227B6 SK 282227 B6 SK282227 B6 SK 282227B6 SK 74995 A SK74995 A SK 74995A SK 282227 B6 SK282227 B6 SK 282227B6
Authority
SK
Slovakia
Prior art keywords
moxonidine
patients
treatment
parts
plasma glucose
Prior art date
Application number
SK749-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK74995A3 (en
Inventor
Elbert Kaan
Dieter Ziegler
Reinhard Br�Ckner
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Publication of SK74995A3 publication Critical patent/SK74995A3/sk
Publication of SK282227B6 publication Critical patent/SK282227B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Fats And Perfumes (AREA)
SK749-95A 1994-07-01 1995-06-06 Farmaceutický prostriedok na liečenie hyperglykémie SK282227B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4423177A DE4423177A1 (de) 1994-07-01 1994-07-01 Antihyperglykämisch wirksame Arzneimittel

Publications (2)

Publication Number Publication Date
SK74995A3 SK74995A3 (en) 1996-05-08
SK282227B6 true SK282227B6 (sk) 2001-12-03

Family

ID=6522064

Family Applications (1)

Application Number Title Priority Date Filing Date
SK749-95A SK282227B6 (sk) 1994-07-01 1995-06-06 Farmaceutický prostriedok na liečenie hyperglykémie

Country Status (23)

Country Link
US (1) US5712283A (ru)
EP (1) EP0689837B1 (ru)
JP (1) JP3841846B2 (ru)
KR (1) KR100366130B1 (ru)
CN (1) CN1092961C (ru)
AT (1) ATE210444T1 (ru)
AU (1) AU691580B2 (ru)
CA (1) CA2152998C (ru)
CZ (1) CZ287563B6 (ru)
DE (2) DE4423177A1 (ru)
DK (1) DK0689837T3 (ru)
DZ (1) DZ1894A1 (ru)
ES (1) ES2167385T3 (ru)
FI (1) FI117374B (ru)
HU (1) HU226946B1 (ru)
IL (1) IL113411A (ru)
NO (1) NO307029B1 (ru)
NZ (1) NZ270990A (ru)
PT (1) PT689837E (ru)
RU (1) RU2145857C1 (ru)
SK (1) SK282227B6 (ru)
UA (1) UA27954C2 (ru)
ZA (1) ZA954691B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4941796A (en) * 1995-02-28 1996-09-18 Beiersdorf-Lilly Gmbh Use of moxonidine for the treatment of atherosclerosis
CZ397698A3 (cs) * 1996-06-06 1999-05-12 Eli Lilly And Company Prostředky a způsob léčení městnatého srdečního selhání
IL123232A0 (en) * 1997-02-11 1999-11-30 Lilly Co Eli Medicament for inhibiting glucose metabolism deterioration
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
EP0919234A3 (en) * 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine
US6897019B1 (en) * 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
EP1517688A2 (de) * 2002-06-19 2005-03-30 Solvay Pharmaceuticals GmbH Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen
ES2304624T3 (es) * 2003-10-10 2008-10-16 Solvay Pharmaceuticals Gmbh Composicion farmaceutica que comprende un agonista selectivo del receptor de imidazolina l1 y un bloqueador del receptor de angiotensina ii.
RU2542462C2 (ru) * 2013-06-28 2015-02-20 Андрей Владиславович Струтынский Способ коррекции кризового течения гипертонической болезни и абдоминального ожирения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
FI117374B (fi) 2006-09-29
JP3841846B2 (ja) 2006-11-08
FI953256A (fi) 1996-01-02
EP0689837A3 (de) 1996-06-05
NO952624L (no) 1996-01-02
RU2145857C1 (ru) 2000-02-27
AU1775795A (en) 1996-01-18
DE4423177A1 (de) 1996-01-04
IL113411A0 (en) 1995-07-31
EP0689837A2 (de) 1996-01-03
HU9501900D0 (en) 1995-08-28
HUT72599A (en) 1996-05-28
CA2152998A1 (en) 1996-01-02
EP0689837B1 (de) 2001-12-12
DZ1894A1 (fr) 2002-02-17
CN1092961C (zh) 2002-10-23
ZA954691B (en) 1996-01-29
CZ287563B6 (en) 2000-12-13
DK0689837T3 (da) 2002-03-11
FI953256A0 (fi) 1995-06-30
HU226946B1 (en) 2010-03-29
NO307029B1 (no) 2000-01-31
US5712283A (en) 1998-01-27
JPH0840906A (ja) 1996-02-13
PT689837E (pt) 2002-04-29
UA27954C2 (ru) 2000-10-16
KR100366130B1 (ko) 2003-03-26
AU691580B2 (en) 1998-05-21
CZ139395A3 (en) 1996-01-17
KR960003729A (ko) 1996-02-23
ES2167385T3 (es) 2002-05-16
NO952624D0 (no) 1995-06-30
NZ270990A (en) 1997-06-24
SK74995A3 (en) 1996-05-08
IL113411A (en) 1999-07-14
CN1122224A (zh) 1996-05-15
CA2152998C (en) 2002-09-03
DE59509928D1 (de) 2002-01-24
ATE210444T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
JP7479696B2 (ja) グルコキナーゼ活性化剤およびビグアナイド系血糖降下薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用
US4708868A (en) Oral anti-diabetic pharmaceutical forms and the preparation thereof
US20140255486A1 (en) Coated Tablet Formulation and Method
SK282227B6 (sk) Farmaceutický prostriedok na liečenie hyperglykémie
US20150250734A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
EP0880967B1 (de) Nephroprotektive Arzneimittel
US5972948A (en) Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
RU2772875C1 (ru) Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и блокатор к-атф-каналов, способ их приготовления и их применение
JP2688266B2 (ja) アルドース還元酵素阻害作用を有し且つ吸収性の良好な薬剤組成物

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: ABBOTT PRODUCTS GMBH, HANNOVER, DE

Effective date: 20120920

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20140606